Spherocytosis+ + + serum was found to contain an IgG anti-A alloagglutinin at a titre of over 1:512. We believe that this patient had a haemolytic transfusion reaction owing to transfusion of plasma containing high-titre IgG anti-A. Thereafter she was transfused with 0 positive packed cells and had no further immediate haematological problems.
Comment
The ability of IgG "immune" antibodies present in type 0 plasma to cause red-cell destruction when transfused to patients with type A, B, or AB blood is well recognised.3 Haemolysis due to immune anti-A antibody after infusion of factor VIII concentrates has also been reported.4 We are not aware that immune anti-A alloagglutinin has previously been implicated in haemolysis after transfusions of granulocytes.
Subsequently we screened the serum of 13 patients with blood group 0 in chronic-phase chronic granulocytic leukaemia for the presence of high-titre IgG anti-A and anti-B alloagglutinins. We identified three patients with an IgG anti-A titre of over 1:128, in one of whom the IgG anti-B titre was also over 1:128. These three patients were therefore potentially dangerous as plasma donors to recipients with blood groups other than 0. We suggest that if it is necessary to give group 0 granulocytes to patients with group A, B, or AB blood the 0 plasma should first be removed (as for red-cell transfusion) and the cells should be resuspended in AB plasma. This should prevent haemolytic episodes such as the one reported here. Acute renal failure and interstitial nephritis after clofibrate treatment
Clofibrate has been associated with a variety of adverse reactions including acute myalgia,l gall stones,2 a lupus-like syndrome,3 and deterioration of renal function in patients with chronic renal failure.4
The first case is reported here of acute reversible renal failure due to interstitial nephritis after treatment with clofibrate.
Case report
A 51-year-old miner, an insulin-dependent diabetic for 16 years, was started on clofibrate 500 mg 6 hourly because of exudative retinopathy. Three weeks later he developed nausea, a rash, and severe backache. He had noted similar symptoms 12 years earlier when given phenindione after a myocardial infarction. He was admitted four weeks after first taking clofibrate. The results of examination were normal apart from retinopathy and a generalised erythematous rash. His blood pressure was 150/90 mm Hg. Blood concentrations were as follows: urea 29 mmol/l (175 mg/100 ml), plasma sodium 123 mmol(mEq)/l, potassium 5Ommol(mEq)/l, bicarbonate 22 mmol(mEq)/l, glucose 36 mmol/l (649 mg/100 ml), and creatinine 395 ,umol/l (4 5 mg/100 ml). Plasma total protein and albumin concentrations, and creatine phosphokinase activity were normal. Creatinine clearance was 4 ml/min, urinary protein 0-8 g/24 h, and urinary myoglobin absent. The erythrocyte sedimentation rate was 58 mm in 1 h, antinuclear factor negative, platelet count 200 x 109/1 (200 000/mm3), and complement, immunoglobulins, and coagulation studies were normal. An intravenous pyelogram was normal. A renal biopsy specimen showed a heavy cortical and medullary infiltrate of
